

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> <b>C12N 15/62, 9/72, A61K 37/547</b> <b>C12N 15/58</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 92/04450</b> <b>(43) International Publication Date:</b> 19 March 1992 (19.03.92)
<b>(21) International Application Number:</b> PCT/GB91/01455 <b>(22) International Filing Date:</b> 29 August 1991 (29.08.91)  <b>(30) Priority data:</b> 9019120.6 1 September 1990 (01.09.90) GB  <b>(71) Applicant (for all designated States except US):</b> BEECHAM GROUP PLC [GB/GB]; SB House, Great West Road, Brentford, Middlesex TW8 9BD (GB).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only) :</b> DODD, Ian [GB/GB]; BROWN, Michael, Joseph [GB/GB]; ROBINSON, Jeffery, Hugh [GB/GB]; SmithKline Beecham Pharmaceuticals, Great Burgh, Yew Tree Bottom Road, Epsom, Surrey KT18 5XQ (GB).		<b>(74) Agents:</b> VALENTINE, Jill, Barbara et al.; SmithKline Beecham, Corporate Patents, Great Burgh, Yew Tree Bottom Road, Epsom, Surrey KT18 5XQ (GB).  <b>(81) Designated States:</b> AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), SE (European patent), US.  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> HYBRID PLASMINOGEN ACTIVATORS  <b>(57) Abstract</b>  A hybrid fibrinolytic enzyme, its preparation, pharmaceutical compositions containing it and its use in the treatment of thrombotic disease.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU <sup>+</sup>	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE <sup>+</sup>	Germany	MC	Monaco	US	United States of America
DK	Denmark				

<sup>+</sup> Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

HYBRID PLASMINOGEN ACTIVATORS

The present invention relates to a hybrid fibrinolytic enzyme and derivatives thereof, its preparation, pharmaceutical compositions containing it and its use in the treatment of thrombotic disease, in particular acute myocardial infarction.

The sequence of amino acids making up the enzyme tissue-type plasminogen activator (t-PA) and the nucleotide sequence for the cDNA which codes for t-PA are known (see Pennica *et al.*, 1983; Nature, 301, 214). t-PA is known to have fibrinolytic activity.

As used herein, the term tissue-type plasminogen activator (t-PA) denotes a plasminogen activator of the group having the immunological properties defined for t-PA at the XXVIII Meeting of the International Committee on Thrombosis and Haemostasis, Bergamo, Italy, 27 July 1982.

20

The amino acid sequence of various forms of t-PA are known. The abovementioned Nature 1983 reference discloses the sequence for the L-chain and the mature S-chain forms of t-PA, also discussed by Vehar *et al.*, Biotechnology, 1984, 2, 1051-7 in which the processing of initially formed t-PA by removal of a pro-sequence to give the S-chain form is reported. Pohl *et al.*, FEBS letters, 1984, Vol. 168 No.1, 29-32, refers to the N-terminal multiplicity of t-PA and discloses the U-chain form. The numbering system for the amino acid sequence of t-PA used herein is that described in the Nature 1983 reference for mature (S-chain) t-PA in which the N-terminal serine is numbered 1. By this system, L-chain t-PA has an N-terminal glycine residue at position -3 and U-chain t-PA has an N-terminal valine at position 4. References to t-PA herein are understood to include all such variant forms.

-2-

Native t-PA is composed of a B or light and an A or heavy chain. The B-chain contains the active site of the enzyme. The cleavage site for the conversion of t-PA from the single to the two-chain form is located between residues arg-275 and ile-276. In the two-chain form the chains are held together by a disulphide bridge formed between residues cys-264 in the A-chain and cys-395 in the B-chain.

It has been shown (Ny, T. et al, 1984; Proc. Natl. Acad. Sci. U.S.A., 81, 5355) that the A chain exhibits a number of structural and functional domains which are homologous to structures found in other plasma proteins: two triple disulphide-bonded structures or kringles, a growth-factor-like domain and a fibronectin-finger-like domain.

The sequence of amino acids making up the enzyme urokinase-type plasminogen activator (u-PA) in its single chain and two chain forms (Verstraete, M. and Collen, D., 1986; Blood, 67, 1529) and the nucleotide sequence for the cDNA which codes for human u-PA (Holmes, W. E. et al, 1985; Bio/technology 3, 923-929) are known. Urokinase-type plasminogen activator is known to have fibrinolytic activity. The two chains of u-PA are termed the A- and B-chain. The B-chain contains the active site of the enzyme. The cleavage site for the conversion of u-PA from the single to the two chain form is located between residues lys-158 and ile-159. In the two chain form the chains are held together by a disulphide bridge formed between residues cys-148 in the A-chain and cys-279 in the B-chain.

As used herein, the term urokinase-type plasminogen activator (u-PA) denotes a plasminogen activator of the group having the immunological properties defined for u-PA at the XXVIII Meeting of the International Committee on Thrombosis and Haemostasis, Bergamo, Italy, 27 July 1982.

-3-

The numbering system for the amino acid and nucleotide sequence of u-PA used herein is that described in Holmes, W. E. et al., 1985 (op. cit.) in which the N- terminal serine residue is numbered 1.

5

In addition to the native forms of t-PA and u-PA described above, various muteins and hybrids are also known, see for example EP-A-0201153, EP-A-0233013, EP-A-0199574, WO 86/01538, EP-A-0227462, EP-A-0253582, WO 86/04351,

10 EP-A-0236040, EP-A-0200451, EP-0225286, DE 3537176, WO 87/04722, WO 90/02798, EP 0299706, WO 89/04368, WO 90/00600, WO 90/02798 and PCT/GB91/00801 (incorporated herein by reference).

15 References herein to t-PA and u-PA species include both native forms and muteins.

Plasmin is a two-chain serine protease which may be obtained by the cleavage of the single chain precursor, plasminogen, 20 at a specific internal peptide bond. The amino acid sequence of human plasminogen is known (Wiman and Walters (1975) Eur.J. Biochem. 50, 489-494 and 58, 539-547; Wiman (1977) Eur. J. Biochem. 76, 129-137; Sottrup-Jensen et al. (1978) Fibrinolysis and Thrombolysis Vol. 3, 191-209, Raven Press, New York; and Sottrup-Jensen et al. (1978) Atlas of Protein Sequence and Structure Vol. 5, Suppl. 3, p91, National Biomedical Research Foundation, Silver Spring, MD). A partial nucleotide sequence coding for amino acid residues 272-790 of human plasminogen has also been described 25 (Malinowski, D.P. et al., 1984, Biochemistry, 23, 4243-4250). The cleavage site of human plasminogen is located between residues arg-560 and val-561 (according to the sequence numbering of Sottrup-Jensen et al. (1978) Atlas of Protein Sequence (op.cit.)). Two species of plasminogen 30 have been identified ( F.J. Castellino, Chemical Reviews Vol. 81 p431 (1981)): glu<sub>1</sub> which has an N-terminal glutamic acid residue at position 1 and lys<sub>77</sub> which has an N-terminal

-4-

lysine residue at position 77. Glu-plasminogen is also easily converted by limited plasmin digestion to other modified forms with N-terminal valine (val<sub>78</sub>) or methionine (met<sub>68</sub>) (C. Miyashita, E. Wenzel and M. Heiden, Haemostasis 5 18, supp.1 pp 7-13 (1988)). References to plasminogen herein are understood to include all these species.

A complete nucleotide sequence has also been described (Forsgren, M., et al., 1987, FEBS Letters 213, 254-260).  
10 The nucleotide sequence predicts the existence of an extra, previously unreported, isoleucine residue near the N-terminus of the A-chain. This finding has been independently confirmed (McLean, J.N., et al., 1987, Nature 330, 132-137). Accordingly all sequence numbering (amino  
15 acid and nucleotide) below follows Forsgren et al. (1987). In this numbering sequence the plasminogen cleavage site is located between residues arg-561 and val-562 and the N-terminal modified forms are termed met<sub>69</sub>, lys<sub>78</sub> and val<sub>79</sub>.

20 Plasminogen has five kringle structures. The region from the first to the last cysteine residue of each kringle structure, residues 84 to 162, 166 to 243, 256 to 333, 358 to 435 and 462 to 541 inclusive will be referred to herein as the K<sub>1</sub><sup>P</sup>, K<sub>2</sub><sup>P</sup>, K<sub>3</sub><sup>P</sup>, K<sub>4</sub><sup>P</sup> and K<sub>5</sub><sup>P</sup> domains respectively.

25

According to the present invention there is provided a hybrid plasminogen activator which comprises kringle 5 or kringles 4 and 5 of plasminogen linked to the B-chain of t-PA or u-PA via an amino acid sequence comprising,  
30 respectively, the t-PA cleavage site between residues 275 and 276 and the cysteine residue 264 of t-PA or the u-PA cleavage site between residues 158 and 159 and the cysteine residue 148 of u-PA.

-5-

It will be understood that by the term 'B-chain' is meant at least that portion of the B-chain containing the functional active centre of t-PA or u-PA, and preferably comprises residues 276-527 or 159-411 respectively.

5

The linking sequence of amino acids may be introduced synthetically during the preparation of the hybrid plasminogen activator (PA) and/or derived from native sequences.

10

Native plasminogen includes cysteine residues at positions 548 and 558, C-terminal to plasminogen kringle 5, which participate in the interchain disulphide bonds of the two-chain plasmin form. In the preferred embodiment these 15 residues are not present in the linking sequence.

It will be appreciated that to prevent cleavage of the plasminogen kringle(s) from the t-PA or u-PA B-chain in vivo, the linking sequence should be chosen so as to avoid 20 the presence of a site susceptible to trypsin-like proteolytic cleavage N-terminal to residue cys-264 of t-PA or cys-148 of u-PA, as appropriate.


Where the B-chain of t-PA is employed, the linking sequence 25 of amino acids preferably comprises t-PA residues 264 to 275 inclusive, more preferably residues 262 to 275 inclusive.

Where the B-chain of u-PA is employed, the linking sequence of amino acids preferably comprises u-PA residues 148 to 158 30 inclusive, more preferably residues 137 to 158 inclusive.

In one preferred aspect, the hybrid PA may be represented symbolically as:

---


-6-



where  $B^t$  comprises residues 276-527 of t-PA,  $m$  is 0 or 1,  $K_4^P$  and  $K_5^P$  represent kringle domains 4 and 5 derived from plasminogen and each of  $Z_3$ ,  $Z_4$  and  $Z_5$  represents, as appropriate, an optional N-terminal amino acid sequence or a bond or a linking sequence of amino acids which may be introduced synthetically during the preparation of the hybrid PA and/or derived from native plasminogen and/or t-PA sequences, the sequence  $Z_5$  comprising at least residues cys-264 and arg-275 of t-PA.

In a second preferred aspect, the hybrid PA may be represented symbolically as:

15



where  $B^u$  comprises residues 159-411 of u-PA and each of  $Z_3$ ,  $Z_4$  and  $Z_5$  represents, as appropriate, an optional N-terminal amino acid sequence or a bond or a linking sequence of amino acids which may be introduced synthetically during the preparation of the hybrid PA and/or derived from native plasminogen and/or u-PA sequences, the sequence  $Z_5$  comprising at least residues cys-148 and lys-158 of u-PA and  $m$ ,  $K_4^P$  and  $K_5^P$  are as previously defined.

Where  $m$  is 1, the sequence  $Z_3$  preferably has at its N-terminus the sequence [GARSYQ] or [SYQ] corresponding to the L- and S-chain forms of t-PA, and comprises some or all of the native plasminogen inter-domain sequence between plasminogen kringle domains 3 and 4, preferably plasminogen residues 347-357.

When  $m$  is 0, the sequence  $Z_4$  preferably has at its N-terminus the sequence [GARSYQ] or [SYQ] corresponding to



-7-

the L- and S-chain forms of t-PA, and comprises some or all of the native plasminogen inter-domain sequence between plasminogen kringle domains 4 and 5, preferably plasminogen residues 443-461.

5

Where m is 1, Z<sub>4</sub> preferably represents the native plasminogen inter-domain sequence between plasminogen kringle domains 4 and 5.

10 Suitable sequences (Z<sub>5</sub>) linking the plasminogen kringle 5 domain to the t-PA B-chain include:

1. [AAPSTCGLRQYSQPQFR]
2. [AAPSTCGLRQYSQPQFQ]
- 15 3. [STCGLRQYSQPQFR]

(single letter amino acid notation) from which it can be seen that the sequences 1 and 2 consist of residues 542-544 of plasminogen and residues 263 to 275 of t-PA linked by a  
20 serine residue. The interposed serine residue can be identified with ser-545 of plasminogen or ser-262 of t-PA. In sequence 2, residue 275 of t-PA has been replaced by glutamine in accordance with EP-A-0233013. The preferred sequence 3 consists of residues 262 to 275 of t-PA.

25

The preferred sequence (Z<sub>5</sub>) linking the plasminogen kringle 5 domain to the u-PA B-chain is:

[AAPSFPSSPPEELKFQCGQKTLRPRFK]

30

(single letter amino acid notation) from which it can be seen that the sequence consists of residues 542-546 of plasminogen and residues 137 to 158 of u-PA.

-8-

The preferred hybrid PA's of the invention have the following structures:

1. [GARSYQ] Plg 347-541[STCGLRQYSQPQFR]B<sup>t</sup>
- 5 2. [GARSYQ] Plg 443-541[STCGLRQYSQPQFR]B<sup>t</sup>

where Plg x-y represents residues x-y of plasminogen, B<sup>t</sup> is as previously defined and the symbols in brackets represent amino acid residues according to the single letter amino  
10 acid notation, including one and two chain variants, L- and S-chain variants, and mixtures thereof.

The hybrid PA of the invention may be derivatised to provide pharmaceutically useful conjugates analogous to known  
15 PA-containing conjugates, for example:

- (a) an enzyme-protein conjugate as disclosed in EP-A-0 155 388, in which the catalytic site on the enzyme which is responsible for fibrinolytic activity is blocked by a human  
20 protein attached thereto by way of a reversible linking group;
- (b) an enzyme-protein conjugate as disclosed in EP-A-0152 736, comprising at least one optionally blocked fibrinolytic  
25 enzyme linked by way of a site other than the catalytic site responsible for fibrinolytic activity to at least one human protein;
- (c) a protein-polymer conjugate as disclosed in  
30 EP-A-0183503 comprising a pharmaceutically useful protein linked to at least one water soluble polymer by means of a reversible linking group; or
- (d) an enzyme conjugate as disclosed in EP-A-0184363  
35 comprising a plurality of fibrinolytic enzymes linked

-9-

together through the active centres thereof by means of a removable blocking group.

The hybrid PA of the invention may take the place of a PA as the enzyme or (human) protein component, as appropriate, of any of the conjugates described above.

The above mentioned derivatives of the hybrid PA may be used in any of the methods and compositions described hereinafter for the hybrid PA itself.

In a further aspect, the invention provides a process for preparing hybrid plasminogen activator according to the invention which process comprises expressing DNA encoding said hybrid plasminogen activator in a recombinant host cell and recovering the hybrid plasminogen activator product.

The DNA polymer comprising a nucleotide sequence that encodes the hybrid PA also forms part of the invention.

20

The process of the invention may be performed by conventional recombinant techniques such as described in Maniatis *et. al.*, Molecular Cloning - A Laboratory Manual; Cold Spring Harbor, 1982 and DNA Cloning vols I, II and III (D.M. Glover ed., IRL Press Ltd).

In particular, the process may comprise the steps of:

i) preparing a replicable expression vector capable, in a host cell, of expressing a DNA polymer comprising a nucleotide sequence that encodes said hybrid plasminogen activator;

ii) transforming a host cell with said vector;

35

-10-

- iii) culturing said transformed host cell under conditions permitting expression of said DNA polymer to produce said hybrid plasminogen activator; and
- 5 iv) recovering said hybrid plasminogen activator.

The invention also provides a process for preparing the DNA polymer by the condensation of appropriate mono-, di- or oligomeric nucleotide units.

10

The preparation may be carried out chemically, enzymatically, or by a combination of the two methods, in vitro or in vivo as appropriate. Thus, the DNA polymer may be prepared by the enzymatic ligation of appropriate DNA  
15 fragments, by conventional methods such as those described by D. M. Roberts et al in Biochemistry 1985, 24, 5090-5098.

The DNA fragments may be obtained by digestion of DNA containing the required sequences of nucleotides with  
20 appropriate restriction enzymes, by chemical synthesis, by enzymatic polymerisation, or by a combination of these methods.

Digestion with restriction enzymes may be performed in an  
25 appropriate buffer at a temperature of 20°C-70°C, generally in a volume of 50µl or less with 0.1-10µg DNA.

Enzymatic polymerisation of DNA may be carried out in vitro using a DNA polymerase such as DNA polymerase I (Klenow  
30 fragment) in an appropriate buffer containing the nucleoside triphosphates dATP, dCTP, dGTP and dTTP as required at a temperature of 10°C-37°C, generally in a volume of 50µl or less.

-11-

Enzymatic ligation of DNA fragments may be carried out using a DNA ligase such as T4 DNA ligase in an appropriate buffer at a temperature of 4°C to ambient, generally in a volume of 50µl or less.

5

- The chemical synthesis of the DNA polymer or fragments may be carried out by conventional phosphotriester, phosphite or phosphoramidite chemistry, using solid phase techniques such as those described in 'Chemical and Enzymatic Synthesis of Gene Fragments - A Laboratory Manual' (ed. H.G. Gassen and A. Lang), Verlag Chemie, Weinheim (1982), or in other scientific publications, for example M.J. Gait, H.W.D. Matthes, M. Singh, B.S. Sproat, and R.C. Titmas, Nucleic Acids Research, 1982, 10, 6243; B.S. Sproat and W. Bannwarth, Tetrahedron Letters, 1983, 24, 5771; M.D. Matteucci and M.H. Caruthers, Tetrahedron Letters, 1980, 21, 719; M.D. Matteucci and M.H. Caruthers, Journal of the American Chemical Society, 1981, 103, 3185; S.P. Adams *et al.*, Journal of the American Chemical Society, 1983, 105, 661; N.D. Sinha, J. Biernat, J. McMannus, and H. Koester, Nucleic Acids Research, 1984, 12, 4539; and H.W.D. Matthes *et al.*, EMBO Journal, 1984, 3, 801. Preferably an automated DNA synthesizer is employed.

- 25 The DNA polymer is preferably prepared by ligating two or more DNA molecules which together comprise a DNA sequence encoding the hybrid PA.

- The DNA molecules may be obtained by the digestion with  
30 suitable restriction enzymes of vectors carrying the required coding sequences.

- The precise structure of the DNA molecules and the way in which they are obtained depends upon the structure of the  
35 desired hybrid PA product. The design of a suitable

-12-

strategy for the construction of the DNA molecule coding for the hybrid PA is a routine matter for the skilled worker in the art.

5 The expression of the DNA polymer encoding the hybrid PA in a recombinant host cell may be carried out by means of a replicable expression vector capable, in the host cell, of expressing the DNA polymer. The expression vector is novel and also forms part of the invention.

10

The replicable expression vector may be prepared in accordance with the invention, by cleaving a vector compatible with the host cell to provide a linear DNA segment having an intact replicon, and combining said linear  
15 segment with one or more DNA molecules which, together with said linear segment, encode the hybrid PA, under ligating conditions.

The ligation of the linear segment and more than one DNA  
20 molecule may be carried out simultaneously or sequentially as desired.

Thus, the DNA polymer may be preformed or formed during the construction of the vector, as desired.

25

The choice of vector will be determined in part by the host, which may be a prokaryotic cell, such as E. coli or Streptomyces sp., or a eukaryotic cell, such as a mouse C127, mouse myeloma, human HeLa, Chinese hamster ovary,  
30 filamentous or unicellular fungi or insect cell. The host may also be a transgenic animal. Suitable vectors include plasmids, bacteriophages, cosmids and recombinant viruses, derived from, for example, baculoviruses and vaccinia.

35 The preparation of the replicable expression vector may be carried out conventionally with appropriate enzymes for

-13-

restriction, polymerisation and ligation of the DNA, by procedures described in, for example, Maniatis *et al.*, cited above. Polymerisation and ligation may be performed as described above for the preparation of the DNA polymer.

5 Digestion with restriction enzymes may be performed in an appropriate buffer at a temperature of 20°-70°C, generally in a volume of 50µl or less with 0.1-10µg DNA.

The recombinant host cell is prepared, in accordance with  
10 the invention, by transforming a host cell with a replicable expression vector of the invention under transforming conditions. Suitable transforming conditions are conventional and are described in, for example, Maniatis *et al.*, cited above, or "DNA Cloning" Vol. II, D.M. Glover  
15 ed., IRL Press Ltd, 1985.

The choice of transforming conditions is determined by the host cell. Thus, a bacterial host such as *E. coli* may be treated with a solution of CaCl<sub>2</sub> (Cohen *et al.*, Proc. Nat.  
20 Acad. Sci., 1973, 69, 2110) or with a solution comprising a mixture of RbCl, MnCl<sub>2</sub>, potassium acetate and glycerol, and then with 3-[N-morpholino]-propane-sulphonic acid, RbCl and glycerol. Mammalian cells in culture may be transformed by calcium co-precipitation of the vector DNA onto the cells.

25

The invention also extends to a host cell transformed with a replicable expression vector of the invention.

Culturing the transformed host cell under conditions  
30 permitting expression of the DNA polymer is carried out conventionally, as described in, for example, Maniatis *et al.* and "DNA Cloning" cited above. Thus, preferably the cell is supplied with nutrient and cultured at a temperature below 45°C.

35

The hybrid PA expression product is recovered by conventional methods according to the host cell. Thus, where the host cell is bacterial, such as E. coli it may be lysed physically, chemically or enzymatically and the protein product isolated from the resulting lysate. Where the host cell is mammalian, the product may generally be isolated from the nutrient medium.

The DNA polymer may be assembled into vectors designed for isolation of stable transformed mammalian cell lines expressing the hybrid PA; e.g. bovine papillomavirus vectors or amplified vectors in chinese hamster ovary cells (DNA cloning Vol.II D.M. Glover ed. IRL Press 1985; Kaufman, R.J. et al., Molecular and Cellular Biology 5, 1750-1759, 1985; Pavlakis G.N. and Hamer, D.H., Proceedings of the National Academy of Sciences (USA) 80, 397-401, 1983; Goeddel, D.V. et al., European Patent Application No. 0093619, 1983).

It will be appreciated that, depending upon the host cell, the hybrid PA prepared in accordance with the invention may be glycosylated to varying degrees. Furthermore, as observed by Pohl et al., Biochemistry, 1984, 23, 3701-3707, varying degrees of glycosylation may also be found in unmodified, naturally occurring t-PA. Plasminogen also exhibits varying degrees of glycosylation (Hayes M.L, J. Biol. Chem. 254: 8768, 1979). Mutant forms of the hybrid PA are also contemplated in which glycosylation sites are removed by genetic engineering techniques, for example as taught in EP-A-0225286, DE-3537176, WO 87/04722, EP-0299706 or WO 89/04368. The hybrid PA of the invention is understood to include such glycosylated variations.

It will also be appreciated that, depending upon the expression conditions, the hybrid PA prepared in accordance with the invention may exist in the single or two chain forms or mixtures thereof. The invention extends to all



-15-

such forms.

The hybrid PA of the invention comprises the B-chain of native t-PA or u-PA linked to an A-chain comprising kringle 5 or kringles 4 and 5 derived from plasminogen via a linking sequence of amino acids comprising residues 264 and 275 of t-PA or residues 158 and 148 of u-PA.

This hybrid PA A-chain may be employed as one chain of a fibrinolytically active hybrid protein such as disclosed in EP-0 155 387. The hybrid A-chain, DNA encoding the hybrid A-chain and a hybrid protein comprising the hybrid A-chain linked to the B-chain of a fibrinolytically active protease, the catalytic site of which is optionally blocked by a removable blocking group, all form part of the invention.

The hybrid A-chain may be prepared by separation from the B-chain thereof by mild reduction. Alternatively the hybrid A-chain may be prepared by expressing DNA coding therefor in a recombinant host cell and recovering the hybrid A-chain product. The hybrid protein comprising the hybrid A-chain linked to the B-chain of a fibrinolytically active protease may be prepared by (a) mixing said A- and B-chains under oxidative conditions; or (b) ligating DNA encoding said A-chain to DNA encoding said B-chain and expressing the ligated DNA in a prokaryote or eukaryote host; and thereafter optionally blocking the catalytic site of the hybrid protein with a removable blocking group. The oxidation and reduction conditions are as generally described in EP-A-0 155 387.

The resulting hybrid protein may be used in any of the methods and compositions described hereinafter for the hybrid PA itself.

-16-

The hybrid PA of the invention or conjugate thereof can be further derivatised such that any catalytic site essential for fibrinolytic activity is optionally blocked by a removable blocking group.

5 As used herein the expression 'removable blocking group' includes groups which are removable by hydrolysis at a rate such that the pseudo-first order rate constant for hydrolysis is in the range of  $10^{-6} \text{ sec}^{-1}$  to  $10^{-2} \text{ sec}^{-1}$ , more  
10 preferably  $10^{-6} \text{ sec}^{-1}$  to  $10^{-3} \text{ sec}^{-1}$ , in isotonic aqueous media at pH 7.4 at  $37^{\circ}\text{C}$ .

Such blocking groups and blocking reactions are described in European Patent No.0009879 and EP 0297882 and include acyl  
15 groups such as optionally substituted benzoyl or optionally substituted acryloyl.

Suitable optional substituents for benzoyl blocking groups include halogen,  $\text{C}_{1-6}$  alkyl,  $\text{C}_{1-6}$  alkoxy,  $\text{C}_{1-6}$  alkanoyloxy,  
20  $\text{C}_{1-6}$  alkanoylamino, amino or p-guanidino.

Suitable optional substituents for acryloyl blocking groups include  $\text{C}_{1-6}$  alkyl, furyl, phenyl or  $\text{C}_{1-6}$  alkylphenyl.

25 In one aspect, the removable blocking group is a 2-aminobenzoyl group substituted in the 3- or 4-position with a halogen atom and optionally further substituted with one or more weakly electron-withdrawing or electron-donating groups, wherein the pseudo first order rate constant for  
30 hydrolysis of the derivative is in the range  $6.0 \times 10^{-5}$  to  $4.0 \times 10^{-4} \text{ sec}^{-1}$  when measured in a buffer system consisting of 0.05M sodium phosphate, 0.1M sodium chloride, 0.01% v/v detergent comprising polyoxyethylenesorbitan monoleate having a molecular weight of approximately 1300, at pH 7.4  
35 at  $37^{\circ}\text{C}$ .

-17-

Preferably the pseudo first order rate constant for hydrolysis of the derivative is in the range  $6.0 \times 10^{-5}$  to  $2.75 \times 10^{-4} \text{ s}^{-1}$ , preferably  $6.0 \times 10^{-5}$  to  $2.5 \times 10^{-4} \text{ s}^{-1}$ , more preferably  $6.0 \times 10^{-5}$  to  $2.0 \times 10^{-4} \text{ s}^{-1}$ , still more preferably  $6.0 \times 10^{-5}$  to  $1.5 \times 10^{-4} \text{ s}^{-1}$  and most preferably  $7.0 \times 10^{-5}$  to  $1.5 \times 10^{-4} \text{ s}^{-1}$ .

Preferably, the 2-aminobenzoyl group is substituted with a halogen atom in the 4-position.

10

Preferably, the halogen atom is fluorine, chlorine or bromine.

When the group is further substituted, preferred groups include  $\text{C}_{1-6}$  alkyl,  $\text{C}_{1-6}$  alkoxy and  $\text{C}_{1-6}$  alkenyl substituents in the 3- or 5-positions of the ring.

Examples of the blocking group include 4-fluoro-2-aminobenzoyl, 4-chloro-2-aminobenzoyl, 4-bromo-2-aminobenzoyl and p-methoxybenzoyl.

The hybrid PA and derivatives of the invention are suitably administered in the form of a pharmaceutical composition.

Accordingly the present invention also provides a pharmaceutical composition comprising a hybrid PA or derivative of the invention in combination with a pharmaceutically acceptable carrier.

The compositions according to the invention may be formulated in accordance with routine procedures as pharmaceutical compositions adapted for intravenous administration to human beings.

Typically compositions for intravenous administration are solutions of the sterile enzyme in sterile isotonic aqueous

-18-

buffer. Where necessary the composition may also include a solubilising agent to keep the hybrid PA or derivative in solution and a local anaesthetic such as lignocaine to ease pain at the site of injection. Generally, the hybrid PA or derivative will be supplied in unit dosage form for example as a dry powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of protein in activity units. Where composition comprises a derivative of the invention or where the hybrid PA includes a removable blocking group, an indication of the time within which the free protein will be liberated may be given. Where the protein is to be administered by infusion, it will be dispensed with an infusion bottle containing sterile pharmaceutical grade 'Water for Injection' or saline. Where the protein is to be administered by injection, it is dispensed with an ampoule of sterile water for injection or saline. The injectable or infusible composition will be made up by mixing the ingredients prior to administration.

20

The quantity of material administered will depend upon the amount of fibrinolysis required and the speed with which it is required, the seriousness of the thromboembolic condition and position and size of the clot. The precise dose to be employed and mode of administration must per force in view of the nature of the complaint be decided according to the circumstances by the physician supervising treatment. However, in general, a patient being treated for a thrombus will generally receive a daily dose of from 0.01 to 10 mg/kg of body weight, such as 0.10 to 2.0mg/kg, either by injection in for example up to five doses or by infusion.

Within the above indicated dosage range, no adverse toxicological effects are indicated with the compounds of the invention.

-19-

Accordingly, in a further aspect of the invention there is provided a method of treating thrombotic diseases, which comprises administering to the sufferer an effective non-toxic amount of hybrid PA or derivative of the  
5 invention.

In another aspect the invention provides the use of a hybrid PA or derivative of the invention for the manufacture of a medicament for the treatment of thrombotic diseases.

10

The invention also provides a hybrid PA or derivative of the invention for use as an active therapeutic substance and in particular for use in the treatment of thrombotic diseases.

15 The following Methods and Examples illustrate the invention.

I. General Methods used in Examples(i) DNA cleavage

5 In general the cleavage of about 1µg of plasmid DNA or DNA fragments was effected using about 5 units of a restriction enzyme (or enzymes) in about 20µl of an appropriate buffer solution.

10 (ii) Ligation of DNA fragments

Ligation reactions were carried out as described in Maniatis et al, (Molecular Cloning - A Laboratory Manual, Cold Spring Harbor Laboratory, 1982).

15

(iii) Transformation of plasmid DNA into E.coli HB101 cells used competent HB101 supplied by Gibco BRL (Paisley, Scotland), according to the manufacturers instructions.

20 (iv) Plasmid preparation

Preparation of plasmid DNA was carried out as described in Maniatis et al, (Molecular Cloning - A Laboratory Manual, Cold Spring Harbor Laboratory, (1982)).

25

(v) Isolation of DNA fragments from low-melting-point (LMP) agarose gels

DNA fragments were isolated from LMP agarose gels as  
30 described by Maniatis et al, (Molecular Cloning-A Laboratory Manual, Cold Spring Harbor Laboratory, 1982). Alternatively the excised gel band was purified using GENECLAN<sup>tm</sup>,

-21-

(Stratech Scientific, London) used according to the manufacturers instructions.

(vi) Oligonucleotides

5

Oligonucleotides were made on Applied Biosystems 381A DNA Synthesizer according to the manufacturers instructions. When used in plasmid construction the oligonucleotides were annealed by heating together at 95°C for 5 minutes and  
10 cooling slowly to room temperature. The annealed oligonucleotides were then ready for ligation.

(vii) DNA sequencing by double-strand method

15 Sequencing was carried out using 'Sequenase<sup>TM</sup> (United States Biochemical Corporation) essentially according to the manufacturers instructions.

(viii) Transient expression of plasminogen activators from  
20 HeLa cells

(a) Small-scale

Cell preparation: cells were trypsinised and plated out at  
25 approx.  $2.4 \times 10^5$  cells per 35mm dish and incubated in 1.5ml growth medium (this is Hepes buffered RPMI 1640 medium (041-02400) containing 10% Serum (021-06010), 2% sodium bicarbonate solution (043-05080),; Gibco, Paisley, Scotland) at 37°C in a humidified incubator in an atmosphere of 5%  
30 CO<sub>2</sub>/95% air. After 72h the cells were refed, and used for transfection 24h later.

Transfection procedure: Cultures were changed to Eagles MEM (041-01095), 10% serum (021-06010), and 1% non-essential  
35 amino acids (043-01140) 3h before transfection. The transfections used calcium coprecipitation as described in

-22-

'DNA Cloning' Ed. D.M. Glover (Chap. 15, C. Gorman).  
Glycerol shock and 5mM butyrate treatments were used.  
Plasminogen activator(s) secreted by transfected cells was  
harvested in 1.0ml RPMI 1640 medium (as above, but lacking  
5 serum) + 4% Soybean Peptone.

(b) Large-scale

Cell preparation: cells were trypsinised and plated out at  
10 a density of approx.  $2.5 \times 10^6$  cells per  $175\text{cm}^2$  flask in  
30ml growth medium (above). After 72h an extra 25ml of  
growth medium was added and the cells were used for DNA  
transfection 24h later (as above). 25ml of harvest medium  
were used per flask.

15

Alternatively the cells were plated at a density of  
approximately  $2.0 \times 10^6$  cells per flask and 25ml of growth  
medium was added after 96h incubation and the cells used as  
above.

20

The two seeding rates and feed times used in the small and  
large-scale protocols were designed to allow convenient  
timing of experiments. Both sets of protocols allow  
efficient expression of activator(s).

25

(ix) Chromogenic substrate assays

Hybrid was assayed against the chromogenic substrate S-2288  
(KabiVitrum, Sweden) at a substrate concentration of 1mM in  
30 0.1 M triethanolamine.HCl pH 8.0 at  $25^\circ\text{C}$ . An SU is defined  
as the amount of activity that gives an O.D. increase at  
405nm of 0.001/min in 0.5 ml substrate in a 1 cm pathlength  
cell.

35 In another form of the assay, specifically designed for the  
semi-quantitative assay of chromatography column fractions,  
10 $\mu$ l of each fraction was mixed with 100 $\mu$ l 1mM S-2288 (as



-23-

above) in wells of a microtitre plate and the plate incubated at 37°C until such time as yellow colour was visible. The solutions were read at 410 nm using a Dynatech MR700 Microplate reader.

5

(x) Fibrinolytic activity assay

The fibrinolytic activity of hybrid plasminogen activator solutions was measured on human plasminogen-containing  
10 fibrin plates as described (Dodd, I., and Carr, K., Thrombosis Res. 1989 55 79-85). Dose-responses of hybrid plasminogen activators had slightly different slopes to those of the tissue-type plasminogen activator standard so all activities are approximate. Activities are expressed in  
15 IU with reference to the 2nd International standard for t-PA, Lot 86/670, unless otherwise stated.

(xi) Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS PAGE)

20

SDS PAGE was carried out to determine the apparent molecular weight(s) of the hybrid plasminogen activators using essentially the method of Laemmli (Nature 1970 227 680-685). The activators were identified either by staining for  
25 protein or by a fibrin zymography technique (Dodd, I. et al Thromb. Haemostasis 1986, 55 94-97). Using these methods it was generally possible to determine chain nature (sc v tc).

(xii) Rate constant determinations

30

Acyl-enzyme (ca. 20 pmol, 10µl) was added to a solution of S-2288 (0.5ml of 1.0mM in 0.05M sodium phosphate, 0.1M NaCl, 0.01% w/v Tween 80 pH (37°C) 7.4) in a spectrophotometer cuvette thermostatted at 37°C. Absorbance readings at

-24-

405nm were recorded at 1.0 min intervals for 30 min and on-board software (Beckman Inc.) used to calculate the rate of change of absorbance over each successive 1 min interval. As deacylation proceeded in the cuvette, the rate of change of A405nm increased with time. Rate data obtained when the absorbance exceeded a value of 0.8 were not used because of the effect of substrate depletion. The set of rate determinations were fitted to the following monoexponential function:

10

$$f(t) = A_0 + (A_{\max} - A_0) \times (1 - e^{-kt})$$

where  $A_0$  is the initial activity of the acyl-enzyme and  $A_{\max}$  is the maximum activity possible after deacylation and was determined by deacylation of an aliquot of acyl-enzyme in 0.1M Tris. HCl, 20% w/v glycerol, 0.14M NaCl, 0.01% w/v Tween 80 pH 7.4 at 37°C for 1h followed by amidolytic assay with S-2288 under the above conditions (i.e. phosphate buffer pH 7.4, 37°C).  $A$  and  $K$ , the first order deacylation rate constant, were treated as unknowns in the fitting process and were derived by non-linear regression analysis on a VAX 11/750 computer.

## II. Identification of nucleotides, amino acid residues, N-termini, protein domains and chain nature in the examples

### (1) Sequences

All t-PA numbering as in Pennica et al (1983) op. cit.; plasminogen amino acid numbering based on Sottrup-Jensen et al (1978) Atlas of Protein Sequence and Structure Vol. 5, Suppl. 3, p91, National Biomedical Research Foundation, Silver Spring, MD., but updated to include the extra amino acid residue identified by Forsgren, M. et al (1987) FEBS

Letters, 213, 254-260. Plasminogen nucleotide sequences as in Forsgren et al. (op.cit.).

(ii) Protein Domains

5

The protein domains described in the examples have been abbreviated for convenience and are defined as follows:-

1. B<sup>t</sup> = t-PA amino acid residues 276 to 527 inclusive.
- 10 2. K<sub>4</sub>P = plasminogen amino acid residues 358 to 435 inclusive.  
K<sub>5</sub>P = plasminogen amino acid residues 462 to 541 inclusive.

15

(iii) Chain nature

sc, indicates that the protein is in single chain form.

20 tc, indicates that the protein is in two chain form.

(iv) Vectors

pTRE12 - (EP-0201153)-basic expression vector

25

pTRE15 - (EP-0201153)-encodes wild-type t-PA

pUC8 - a commercially available vector (Gibco-BRL)  
containing a multiple cloning site and a gene that  
30 confers ampicillin resistance.

Example 1Construction of pDH55 encoding SYQ/Plasminogen 347-541/t-PA 262-527 (H55)

5

The construction of pDH55 was carried out as a two step process. This plasmid comprises a cDNA encoding the t-PA signal sequence (-35 to -1) linked to the above hybrid plasminogen activator. The restriction sites used below were located as follows:-

Styl : plasminogen nucleotide 1210

SstI : t-PA nucleotide 1417

15

BamHI : located in SV40 polyA/t intron fragment of pTRE15

BglII : t-PA nucleotide 187

20

a) Construction of the plasmid pDH55i (a holding vector containing the sequence encoding SYQ/Plasminogen 347-541/t-PA 262-410)

25 Two fragments were prepared by restriction digestion and agarose gel electrophoresis. These fragments were as follows.

Fragment 1: was the large fragment from an SstI/BglII  
30 digest of a pUC8 derivative containing a modified multiple cloning site.

Structure of the modified cloning site:-

HindIII SstI  
 5' AGCTTGGGCGCCTTCATTTCCCTCCTCTCCTCCAGAAGAGCTCAAATTT  
 3' ACCCGCGGAAGTAAAGGGAGGAGAGGAGGTCTTCTCGAGTTTAAA

5 BglIII HindIII  
 CAGTGTGGCCAGATCTA  
 GTCACACCGGTCTAGATTCGA

Fragment 2: was an approximately 1kb Styl/SstI fragment from  
 10 pTRH37 (as described in EP-A 0297 882) encoding most of  $K_4P$ ,  
 $K_5P$  and part of  $B^t$ .

These two fragments were ligated together with an  
 oligonucleotide linker (Linker 3) to form plasmid pDH55i.  
 Linker 3 (designed to encode the tripeptide SYQ and  
 15 amino-acid residues 347-359 of plasminogen) was formed by  
 annealing two oligonucleotides (A) and (B) of sequence:-

5' GATCTTACCAAGCACCTGAGCTAACCCCTGTGGTCCAGGACTGCTAC  
 (A)

20  
 5' CATGGTAGCAGTCCTGGACCACAGGGGTTAGCTCAGGTGGTGCTTGGTAA  
 (B)

The DNA was transformed into E.coli HB101 cells. A plasmid  
 25 (pDH55i) was isolated which has the structure shown in  
 Fig.1.

b) Construction of the plasmid pDH55

30 Three fragments were prepared by restriction digestion and  
 agarose gel electrophoresis. These fragments were as  
 follows:-

Fragment 4: was an approximately 1kb BglII/SstI fragment  
 35 from pDH55i encoding the first three amino acids (SYQ) of  
 t-PA, residues 347-357 of plasminogen,  $K_4PK_5P$  and part of

B<sup>t</sup>.

Fragment 5: was an approximately 1.6kb SstI/BamHI fragment from pTRH37 encoding the C-terminal part of B<sup>t</sup> and vector 5 sequences.

Fragment 6: was a BamHI/BglII fragment derived from pTRE15 encoding vector sequences and the t-PA signal sequence. These three fragments were ligated together and transformed 10 into E.coli HB101 cells.

A plasmid was isolated which has the structure shown in Fig.2. The plasmid, when introduced into HeLa cells, directed the expression of a novel plasminogen activator.

15

#### Example 2

#### Purification and Characterisation of H55 Protein

20 Conditioned medium from twenty 175cm<sup>2</sup> HeLa cultures transfected with the plasmid pDH55 was centrifuged at approximately 9000g for 30 min. The supernatant (480ml) was buffer-exchanged into PBS'A' (Dulbecco)/0.01% Tween 80 pH 7.4 using a column (i.d., 90mm;h,226 mm) of Sephadex G25 and 25 a 710ml fraction eluting immediately after the void volume of the column was obtained. The 710 ml fraction was then purified in a similar way to that described for t-PA (Dodd, I. et al FEBS Lett., (1986) 209 13-17). The zinc chelate and lysine Sepharose Fast Flow columns had volumes of 90ml 30 and 10ml respectively. Protein H55 was dissociated from the lysine Sepharose column using a 0.5M arginine-containing buffer; peak H55 - containing fractions were identified by a microtitre plate S2288 assay and were pooled and were ultrafiltered using a membrane with a nominal molecular 35 weight cut off of 10,000 (YM10, Amicon) to a final volume of

-29-

2.2ml. This retentate was regarded as the H55 product.

Fibrin plate assay showed that the original, conditioned harvest medium contained approximately 17000 IU and that the product contained approximately 22000 IU. This difference is believed to be within the natural error in the assay.

Analysis of the product by SDS PAGE followed by protein staining showed a major band at approx apparent  $M_r$  60,000 (non-reduced) or two major bands at  $M_r$  36,000 and 31,000 (reduced). The  $M_r$  36,000 band is known to be the t-PA B-chain moiety; the 31,000 band is presumed to be the  $K_4^P+K_5^P$  moiety. These results suggest the majority of the material is in the two-chain form.

15

Analysis of the retentate by SDS PAGE followed by fibrin zymography indicated a major (approximately 95%) fibrinolytic species at apparent  $M_r$  60,000; so the fibrinolytic activity and the major stainable band co-migrate on SDS PAGE.

### Example 3

#### Synthesis of N,N-dimethyl-4-aminobenzoyl two chain H55

25 (DAB-H55)

1.0ml of the ultrafiltered retentate described in Example 2 (containing 9900 IU; 10,000 SU; nominal 0.8nmol); was mixed with 0.48ml 0.02M Tris/0.2M NaCl/0.2M arginine/0.01% Tween 80 pH 7.0 (Buffer A) and 7.5 $\mu$ l 20mM 4' amidinophenyl-N,N-dimethyl-4-aminobenzoate. HCl (dissolved in DMSO). The mixture was incubated for 1h at 25°C and the S2288 activity of the solution measured; only 2% of the input activity remained. The mixture was buffer-exchanged into Buffer A using a prepacked column (PD10) of Sephadex G25. The final product had a volume of 2.5ml. Fibrin plate assay showed

-30-

the solution contained 8000 IU; the 52288 activity was 450 SU. These figures indicate that the activity is being regenerated during the longer incubation on the fibrin plates i.e., that deacylation is occurring.

5

Example 4Construction of pDH56 encoding SYQ/Plasminogen 443-541/t-PA 262-527 (H56)

10

The construction of pDH56 was carried out as a two step process. This plasmid comprises a cDNA encoding the t-PA signal sequence (-35 to -1) linked to the above hybrid plasminogen activator. The restriction sites used during construction were as follows:-

HinF1: plasminogen nucleotide 1498  
AlwN1: t-PA nucleotide 1130  
Sst1 : t-PA nucleotide 1417  
20 BamH1: located in SV40 polyA/t intron  
fragment of pTRE15  
BglII: t-PA nucleotide 187

a) Construction of the plasmid pDH56i (a holding vector  
25 containing the sequence encoding SYQ/Plasminogen  
443-541/t-PA 262-410)

Three fragments were prepared by restriction digestion and agarose gel electrophoresis. These fragments were as  
30 follows:-

Fragment 1: was from an Sst1/BglII digest of a pUC8 derivative containing a modified linker region. (as described in Example 1).

35



-31-

Fragment 7: was an approximately 411bp *HinF1*/*AlwN1* fragment from pTRH37 (as described in EP-A-0297 882) encoding part of the  $K_4^P$ - $K_5^P$  bridge, the whole of  $K_5^P$  and part of  $B^t$ .

Fragment 8: was an approximately 292bp *AlwN1*/*Sst1* fragment from pTRH37 (as described in EP-A-0297 882) encoding part of  $B^t$ .

These three fragments were ligated together with an oligonucleotide linker (Linker 9) to form plasmid pDH56i. Linker 9 (designed to encode the tripeptide SYQ and amino-acid residues 443-455 of plasminogen) was formed by annealing two oligonucleotides C and D of sequence:-

5' (C)  
GATCTTACCAAGTAGCACCTCCGCCTGTTGTCCTGCTTCCAGATGTAGAG 3'

5' (D)  
AGTCTCTACATCTGGAAGCAGGACAACAGGCGGAGGTGCTACTTGGTAA 3'

20

The DNA was transformed into *E. coli* HB101 cells. A plasmid (pDH56i) was isolated which has the structure shown in Fig.3.

25 b) Construction of the plasmid pDH56

Three fragments were prepared by restriction digestion and agarose gel electrophoresis. These fragments were as follows:-

30

Fragment 10: was an approximately 750bp *BglII*/*Sst1* fragment from pDH56i encoding the first three amino acids of t-PA (SYQ), residues 443 to 461 of plasminogen,  $K_5^P$  and part of  $B^t$ .

35

Fragment 5: was an approximately 1.6kb *Sst1*/*BamH1* fragment from pTRH37 encoding the C-terminal part of  $B^t$  and vector

-32-

sequences. (As described in Example 1)

Fragment 6: was a BamHI/BglII fragment derived from pTRE15 encoding vector sequences and the t-PA signal sequence. (As described in Example 1)

These three fragments were ligated together and transformed into E.coli HB101 cells.

10 A plasmid was isolated (pDH56) which has the structure shown in Fig.4. The plasmid, when introduced into HeLa cells, directed the expression of a novel plasminogen activator.

#### Example 5

15

#### Purification and characterisation of H56 protein

Two purifications were carried out, each resulting in a batch of H56 that was characterised extensively. Both purifications were experimental in that it was not clear which affinity columns were best employed; this led to H56 protein not adsorbing to columns and thus rather complicated purification schemes (not helped by affinity matrices performing poorly). For these reasons, the following descriptions indicate the generality of the purifications - factors considered unimportant for the actual purification of H56 are not detailed (e.g. a batch of lysine Sepharose used on one occasion did not adsorb the H56 protein; the reason is not known).

30

(a) Approximately 500ml conditioned medium from HeLa cultures transfected with the plasmid pDH56 was centrifuged at approximately 9000g for 30 min. The supernatant was buffer-exchanged into PBS 'A' (Dulbecco)/0.01% Tween 80 pH

-33-

7.4 (PBS/TW) using a column of Sephadex G25 (Vt 1500ml) and the 780 ml sample eluting immediately after the void volume of the column was retained.

5 The 780ml sample was chromatographed on zinc chelate Sepharose (see Example 2) and aminohexyl Sepharose 4B (AH Sepharose; Sigma chem.Co.). The latter chromatography was carried out as follows.

10 The column (i.d., 15 mm; h, 45 mm; Vt, 8.0 ml) was equilibrated with PBS/TW. The imidazole-eluted fraction from the zinc chelate column was applied and was washed through with PBS/TW. H56 protein was desorbed using 0.02M Tris/0.5M NaCl/0.5M L-arginine/0.01% Tween 80 pH 7.0. All  
15 parts of the chromatography were at 4°C at approximately 100 cm h<sup>-1</sup>. Active fractions (containing H56) were identified using S2288 and then concentrated by stirred-cell ultrafiltration (YM10, Amicon Ltd). The ultrafiltered retentate was regarded as the product.

20

The product showed a dose-response relationship on human fibrin plates slightly different to that of t-PA and exhibited a single major band of fibrinolytic activity at apparent M<sub>r</sub> 40,000 on SDS PAGE followed by fibrin  
25 zymography. This band had the same M<sub>r</sub> as a doublet, possibly triplet, of polypeptides detected after probing Western blots of H56 with a monoclonal directed at the B-chain of t-PA (ESP2, BioScot, U.K.) or an anti-t-PA B chain Ig G preparation (Dodd, I. et al, Thrombos.  
30 Haemostas., 1986 55 94).

(b) Approximately 500ml conditioned media was prepared and chromatographed on Sephadex G25 and zinc chelate Sepharose essentially as described in (a). Some of the H56 was  
35 partially purified on AH-Sepharose and p-aminobenzamidine Sepharose CL4B (pABA Sepharose; Pierce Chem. Co.) resulting in three active fractions. These were pooled, ultra

-34-

filtered (YM10) and the retentate clarified by centrifugation (10,000g/10min). The supernatant was buffer-exchanged into PBS/TW using Sephadex G25 (PD10) and then purified on freshly autoclaved pABA Sepharose (Vt 11ml) using the same protocol as for AH Sepharose described in (a). Material that was eluted from the pABA Sepharose column by the 0.5M arginine buffer was concentrated (stirred-cell ultrafiltration; YM10) and buffer-exchanged into 0.05M sodium phosphate/0.1M sodium chloride/10mg ml<sup>-1</sup> mannitol/50μM E-amino caproic acid/0.01% Tween 80 pH7.4 (Sephadex G25, PD10). The buffer-exchanged material was regarded as the product.

The dose-response of the product on fibrin plates was approximately parallel to that of t-PA; the product contained approximately 3000 IU/ml. SDS PAGE/fibrin zymography and Western blotting studies revealed similar pictures to those obtained for product (a). SDS PAGE (non-reduced) followed by silver staining also showed a major band in the approximate M<sub>r</sub> 40,000 region.

#### Example 6

#### Synthesis of N,N-dimethyl-4-aminobenzoyl two-chain H56 (DAB H56)

2.1ml H56 (1200 IU/ml) from Example 5 (a) was mixed at 25°C with 6μl 4'-amidinophenyl-N,N-dimethyl-4-aminobenzoate.HCl (AP-DAB; 2mM in DMSO) and incubated at 25°C. Additional aliquots of 20mM AP-DAB were added at 30 min (2μl) and 60 min (3μl). At 90 min 6 per cent of the original amidolytic activity remained. The mixture was buffer-exchanged into 0.02M Tris/0.2M NaCl/0.2M L-arginine/0.01% Tween 80 pH 7.0 (2.5ml) and aliquoted and stored at -40°C.

35

'In-cuvette' deacylation (see General Methods, (xii)) revealed that 90 per cent of the product was in the

-35-

acylated (DAB) form. Under the conditions of the deacylation the material had a deacylation half-life of 105 min.

#### 5 Example 7

#### Expression of H55 protein in dhfr<sup>-</sup>Chinese hamster ovary (CHO) cells

10 The strategy used for expression of H55 in CHO DXB11 cells, using an amplifiable dhfr vector, has been described previously in EPA 0297 882.

The cDNA encoding H55 was recovered from pDH55 as a 3.2kb  
15 BamHI/MluI fragment. This fragment was subcloned into pTRH11 (EPA 0297 882) replacing the original 4.1kb MluI/BamHI fragment (which encoded protein H204). The new plasmid was called pDH17. In pDH17, the hybrid and dhfr transcription cassettes are opposed i.e. converge at their  
20 3' ends.

A second plasmid, pDH16, was also prepared. In this plasmid the whole XhoI fragment carrying the H55 transcription cassette (including RSVLTR and SV40 elements : depicted in  
25 EPA 0297 882, pTRH71) is reversed with respect to that in pDH17. The transcription cassettes for dhfr and H55 are therefore transcribed in tandem.

#### Cell preparation

30

CHO cells were trypsinised and plated out at  $6 \times 10^5$  per 90 mm dish and left in growth medium [Hams F12 nutrient media (041-1765) with 1% stock penicillin/streptomycin (043-5070) and 10% foetal calf serum (013-6290); Gibco, Paisley,  
35 Scotland] at 37°C in a humidified incubator, in an atmosphere of 5% CO<sub>2</sub>/95% air. After 18 hrs the growth medium was replaced with transfection medium [Eagles MEM

-36-

(041-1095) with 1% non-essential amino acids (043-1140), 1% stock penicillin/streptomycin (043-5070), and 10% newborn calf serum (021-6010); Gibco, Paisley, Scotland]. After a further 2 hrs the cells were used for DNA transfection.

5

#### Transfection Procedure

The transfection procedure, carried out in transfection medium, used calcium coprecipitation and glycerol shock as described in DNA Cloning Volume II (Ed. D.M. Glover; chapter 6, C. Gorman). Following transfection the cells were maintained in growth medium for 48 hrs under growth conditions (as above), prior to the selection procedure.

#### 15 Selection

Forty eight hours post-transfection the cells were medium changed into selective medium [ $\alpha$ MEM (041-2561) with 2% stock glutamine (043-5030), 1% stock penicillin/streptomycin (043-5070) and 10% dialysed foetal calf serum (063-6300); Gibco, Paisley, Scotland]. The cells were maintained in selective medium for 8-10 days until colonies of dhfr<sup>+</sup> cells appeared.

25 Isolated colonies were grown to confluency in 25 cm<sup>2</sup> flasks and harvested in serum-free medium for 24 hours. Fibrinolytically active protein was detected by fibrin plate assay.

#### 30 Example 8

##### Synthesis of 4-anisoyl-t-PA 1-3/plasminogen 443-541/t-PA 262-527

35 Purified H56 protein from Example 5 (nominal 0.34 nmoles) in 0.05M NaH<sub>2</sub>PO<sub>4</sub>.2H<sub>2</sub>O/0.1M NaCl/0.01% Tween 80/10 mgml<sup>-1</sup>

-37-

mannitol/50 $\mu$ M E-ACA pH 7.4 (0.84ml) was treated with 4-amidinophenyl-4-anisate. HCl (6.8 nmol; 6.8 $\mu$ l) at 25°C. After 90 min the amidolytic activity of the preparation had decreased to 5% of the original activity.

5

The material was buffer-exchanged using Sephadex G25 (PD10) into 0.02M Tris/0.2M NaCl/0.2M L-Arginine/0.01% Tween 80 pH 7.0 and stored at -40°C.

#### 10 Example 9

##### Synthesis of 4-anisoyl-t-PA 1-3/plasminogen 347-541/t-PA 262-527

15 Purified H55 protein from Example 2 (nominal 0.16 nmol) in 0.02M Tris/0.5M NaCl/0.5M L-Arginine/0.01% Tween 80 pH 7.4 (0.3ml) was treated with 4-amidinophenyl-4-anisate. HCl (3.2 nmol; 3.2 $\mu$ l) at 25°C. After 90 min the amidolytic activity of the preparation had decreased to <2% of the  
20 original activity.

The material was buffer-exchanged into 0.02M Tris/0.2M NaCl/0.2M L-Arginine/0.01% Tween 80 pH 7.0 using Sephadex G25 (PD10) and stored at -40°C.

25

- 38 -

Example 10

The elements used in expressing H56 are:

- 5 pAcCL29 Vector: this is based on pAcYM1 (an expression vector in which a unique Bam HI cloning site has been positioned so as to maximise expression using the polyhedrin promoter: Matsura, Y, Possee R.D. Overton, H.A. and Bishop D.H.L [1987] J.Gen.Virol 68, 1233-1250).
- 10 pAcCL29 (Livingstone, C. and Jones I (1989) NAR 17, 2366) was derived from pAcYM1 as follows; an approximately 5Kb EcoRI-XhoI fragment coding for all the signals necessary for efficient expression and recombination were removed
- 15 from pAcYM1, blunt ended and ligated into in-filled EcoRI Hind III sites in pUC118 (Vieira. J. and Messing J. [1987] Meth. Enzy. 153 3-11).

- 20 Wild type virus is: Autographa californica nuclear polyhedrosis virus (AcNPV).

- Cell line: IPLB Sf21 derived from Spodoptera frugiperda. (Vaughan, J.L., Goodwin, R.H., Thompkins, G.J. and McCawley, P. 1977: *In Vitro* 13, 213-217)

25

Method

- An approx. 2.5 kb Hind III - Bam HI (Hind III located at 5' end of untranslated region, Bam HI located 3' to coding region) fragment from pDH56 (Example 4) was cloned into
- 30 the Bam HI site of the baculovirus transfer vector pAcCL29 using the following linker:

- 5'            GATCCGATATCA            3'
- 35 3'            GCTATAGTTCGA 5'

to give pDB769.



- 39 -

This new recombinant baculovirus was used to infect Sf 21 cells and express the H56 gene as a fibrinolytically active product; standard methods were used (Summers, M.D. and Smith, G.E., 1987: "A Manual of Methods for

- 5 Baculovirus Vectors and Insect Cell Culture Procedures", Texas Agricultural Experiment Station Bulletin No. 1555, and modifications described in Page, M.J. and Murphy, V.F., 1988: in J.M. Walker (ed) Methods in Molecular Biology, Vol. 5).

10

Example 11

Expression of H55 in E.coli

- 15 (a) : Construction of the E.coli Expression Vector pDB525

The tac expression vector pDB525 was derived from pKK223-3 (Pharmacia).

- 20 The 3.28 kb SphI-Sca I fragment of pKK223-3 was replaced with the equivalent fragment from pAT153 (Twigg, A.J. and Sherratt, D.J. (1980) Nature, 283, 216-218) to render the plasmid non-mobilisable; this new vector was called PTR550. PTR550 was restricted with EagI and a 1.7kb blunt-ended EcoRI fragment from ptac-l-Iq, encoding the
- 25 lacIq gene, was ligated in to give pDB525 (figure 5A). The presence of the lacIq gene (Calos, M.P. (1978) Nature, 274, 762-765) ensures tight repression of the tac promoter under non-induced conditions.

- 30 (b) : Construction of the H55 Protein E.coli expression vector pDB549

(i) Construction of pTR545

- 35 The approximately 7.8kb fragment of BstEII-BglII-cut pTRH37 (European Patent Application 0297882) was ligated with oligonucleotides 1 and 2

- 1) 5' GTTACCAACTACCTAGACTGGATTTCGTGACAACATGCGACCGTGAGGCCT  
ACTAGGCCAAGCTTA 3'

- 40 -

- 2) 5' GATCTAAGCTTGGCCTAGTAGGCCTCACGGTCGCATGTTGTCACGAATC  
CAGTCTAGGTAGTTG 3'

5 to give pTR545.

This places a convenient HindIII site 3' to the H37 sequence in this plasmid (figure 5A).

10 (ii) Construction of pDB546

The 0.89 kb EcoRI-HindIII fragment of pTR545, encoding most of the H37 B chain was inserted into the expression vector pDB525 between the EcoRI and  
15 HindIII sites to make pDB546. (Figure 5A)

(iii) Construction of pDB545

The approximately 1kb NcoI-Sst I fragment from pTRH37  
20 encoding K<sub>4</sub>PK<sub>5</sub><sup>P</sup> and part of the B chain of t-PA was ligated into EcoRI-SstI-cut pUC19 together with oligonucleotides 3 and 4

- 3) 5' ATTCATGTCTTACCAAGCACCACTGAGCTAACCCCTGTGGTCCAGG  
25 ACTGCTAC 3'

- 4) 5' CATGGTAGCAGTCCTGGACCACAGGGGTTAGCTCAGGTGGTGCTTGGT  
AAGACATG 3'

30 to give pDB545 (Figure 5B).

(iv) Construction of pDB549

The approximately 1kb EcoRI fragment of pDB545 was  
35 ligated into EcoRI-cut and phosphatased pDB546 to give pDB549. (Figure 5C).

(c) : Expression of H55 protein in E.coli

- 41 -

The H55 expression plasmid pDB549 was transformed into E. coli HB101. The transformed host was grown in L-Broth at 37°C to an OD<sub>550</sub> of 0.8-1.0 and expression was induced with 1mM IPTG (isopropyl-β-D-thiogalactopyranoside). Incubation was continued for a further 3 hours. The cells were harvested and disrupted by sonication (Heat Systems-Ultrasonics; 50 x 50%. 5 second pulses at 70W). The insoluble fraction containing H55 protein was separated by centrifugation at 11,000g for 15 minutes at 4°C. It was subsequently renatured following the protocol described by van Kimmenade, A et al; (1988), Eur. J. Biochem.; 173, 105-114. Analysis of this refolded material using the fibrin zymography technique (Dodd et al; (1986) Thromb. Heam; 55 (1) 94-97) showed it to be fibrinolytically active. The apparent molecular weight observed was consistent with the predicted structure.

#### Example 12

#### Construction of pDH55U encoding SYO/Plasminogen 347-546/u-PA 137-411 (H55U)

Construction of the plasmid pDH55U was accomplished by substituting a 620bp MluI-BstXI fragment from pDH55 (Example 1) (MluI site located in RSVLTR promoter, BstXI site at nucleotide 1209 in plasminogen cDNA sequence) for the analogous MluI-BstXI fragment in pTRH25 (EP A 370 711).

The novel hybrid was expressed using HeLa cell system (Methods). Fibrinolytically active protein, as determined by fibrin plate assay, was recovered from the HeLa cell harvest medium.

- 42 -

Example 13Construction of pDH56U encoding SYO/plasminogen 443-546/u-PA 137-411 (H56U)

5

An approximately 5.9 kb MluI - BspMII (MluI in RSVLTR, BspMII at nucleotide 1060 in u-PA cDNA) fragment and a 593 bp AvaII - BspMII (AvaII at 1693 in plasminogen, BspMII at 1060 in u-PA) fragment were isolated from pDH55U (Example 12). These were ligated with a 816 bp MluI - AvaII (MluI in RSVLTR, AvaII at 1693 in plasminogen) fragment from pDH56 (Example 4) to give pDH56U. Fibrinolytically active protein was expressed as for H55U.

15 Example 14Amplification of expression of H55 in CHO cells

The transfections described in Example 7 were carried out with either 10 or 20µg of pDH16 or pDH17. All were then selected as described in Example 7 and were amplified as follows.

Those dishes transfected with 20µg plasmid DNA were grown to confluency and these cells were amplified in methotrexate as mass cultures. Twenty colonies were isolated from dishes transfected with 10µg plasmid DNA (10 for each plasmid) and these were grown to confluency in 25 cm<sup>2</sup> flasks and harvested in serum-free medium for 24hrs. Fibrinolytically active protein was detected by fibrin plate assay and the four clones with the highest activity were chosen for amplification in methotrexate.

The methotrexate concentration was initially 0.05 µM and was increased stepwise to 5 or 10 µM. At 0.1 µM methotrexate the best cell line, as judged by activity on a fibrin plate, was the pDH17-transfected mass culture (17MC). At 1µM methotrexate the 3 best cell lines (the

- 43 -

pDH16-and pDH17-transfected mass cultures (16MC and 17MC) and the pDH17-transfected clone (17.1)) were sub-cloned, giving 12 sub-clones per cell line. The best cell line from these 36 sub-clones plus the 3 parental lines was sub-clone #1 isolated from 16MC i.e., 16MC.1. This sub-clone along with the 6 next best sub-clones, plus the 3 parental lines, were amplified to 5  $\mu$ M and, for 16MC, to 10  $\mu$ M methotrexate. At these methotrexate concentrations the 2 best cell lines were the sub-clone 16MC.1 at 5 $\mu$ M and the parental mass culture 16MC at 10 $\mu$ M methotrexate.

#### Example 15

##### Purification of protein H55U

Approx 45ml conditioned media from HeLa cells transfected with the plasmid pDH55U (see Example 12) and harvested as described in 'General Methods' was centrifuged at 9000g for 30 min and stored at -40°C for 2 months. It was then thawed and the H55U protein isolated by chromatography on Benzamidine Sepharose 6B (Pharmacia). The details are as follows.

A column (i.d., 16 mm; h, 12mm) of Benzamidine Sepharose was equilibrated with PBS 'A' (Dulbecco)/0.01% Tween 80. The conditioned media was applied to the column and was washed through with equilibration buffer followed by 0.02M Tris/0.5M NaCl/0.01% Tween 80 pH 7.4. H55U was then dissociated from the matrix by washing with 0.02M Tris/0.5M NaCl/0.5M L-arginine/0.01% Tween 80 pH7.4. The chromatography was at 4°C at a flow rate of 100 cmh<sup>-1</sup>. The eluant from the column was collected as discrete fractions. Fractions containing the protein H55U were identified using the microtitre-plate based chromogenic substrate assay (General example (ix)) except that S2444 was used instead of S2288. The most active fractions were pooled and were ultrafiltered (YM10, Amicon Ltd) to 2.0 ml (the 'product').

- 44 -

Assay of the product by fibrin plate assay with reference to a u-PA standard showed it contained 100 IU/ml.

Analysis by SDS PAGE followed by fibrin zymography showed  
5 a single major species at apparent  $M_r$  approx. 60,000.

#### Example 16

##### Purification of protein H56U

10

Approx 45ml conditioned media from HeLa cells transfected with the plasmid pDH56U (see Example 13) and harvested as described in 'General Methods' was centrifuged at 9000g for 30 min and stored at -40°C for 2 months. It was then  
15 thawed and the H56U protein isolated by chromatography on Benzamidine Sepharose 6B (Pharmacia). The details are as follows.

A column (i.d., 16mm; h, 15mm) of Benzamidine Sepharose  
20 was equilibrated with PBS 'A' (Dulbecco)/0.01% Tween 80. The conditional media was applied to the column and was washed through with equilibration buffer followed by 0.02M Tris/0.5M NaCl/0.01% Tween 80 pH 7.4. H56U was then dissociated from the matrix by washing with 0.02M  
25 Tris/0.5M NaCl/0.5M L-arginine/0.01% Tween 80 pH 7.4. The chromatography was at 4°C at a flow rate of 100 cm h<sup>-1</sup>. The eluant from the column was collected as discrete fractions. Fractions containing the protein H56U were identified using th microtitre-plate based chromogenic  
30 substrate assay (General example (ix)) except that S2444 was used instead of S2288. The most active fractions were pooled and were ultrafiltered (YM10, Amicon Ltd) to 2.9 ml (the 'product').

35 Assay of the product by fibrin plate assay with reference to a u-PA standard showed it contained 47 IU/ml. Analysis by SDS PAGE followed by fibrin zymography showed a single major species at apparent  $M_r$  approx. 45,000.

Example 17Purification of protein H56 from Spodoptera frugiperda 21  
5 cells

2.0l serum-free conditioned media from a culture of Sf21  
cells that had been infected with recombinant Baculovirus  
encoding H56 (see Example 10) was clarified by filtration  
10 (Whatman No 1) and then adjusted to pH 5.0 using HCl.

H56 was purified from the media using two chromatography  
columns in series.

15 First, the media was passed down a column (i.d., 41mm; h,  
38mm) of S-Sepharose Fast Flow that had been equilibrated  
in 20mM succinate, 10mM EACA pH 5.0. the media was washed  
through with equilibration buffer followed by a gradient  
(in equilibration buffer) of 0 to 1M NaCl. A final rinse  
20 with the 1M NaCl-containing buffer was then carried out.

The eluant was fractionated and assayed using the S2288  
chromogenic substrate assay. The peak H56-containing  
fractions were those collected during the development of  
25 the NaCl gradient and were pooled. The pH of this pool  
was adjusted to 7.0 using NaOH.

The pH 7.0 - adjusted pool was then chromatographed on a  
column (i.d., 16mm; h, 55mm) of zinc chelate Sepharose  
30 that had been equilibrated in PBS 'A' (Dulbecco)/0.01%  
Tween 80. After application of the pool from the S-  
Sepharose the zinc chelate was washed with equilibration  
buffer followed by 0.02M sodium phosphate/0.3M NaCl/0.01%  
Tween 80 pH 7.4 and then 0.02M sodium phosphate/0.3M  
35 NaCl/0.05M imidazole/0.01% Tween 80 pH 7.4.

H56-containing fractions were identified by S2288  
substrate assay and were pooled. The pool had a volume of

- 46 -

44 ml and contained 100,000 IU by fibrin plate assay with reference to a u-PA standard curve. This particular pool was not analysed by SDS PAGE. However, other purified H56 batches, prepared under almost identical conditions, were analysed under non-reducing conditions. On silver-staining, a single major band at apparent  $M_r$  approximately 40,000 was evident.

### Example 18

10

#### Purification of protein H55 from CHO cells

Two methods were used to purify H55 from CHO cells (see Example 14).

15

(1) 500ml serum-free conditioned media from the CHO mass culture 17MC (amplified to 100nM methotrexate) was applied to zinc chelate Sepharose ( $V_t = 9\text{ml}$ ) and lysine Sepharose ( $V_t = 2\text{ml}$ ) essentially as described (Dodd, I. *et al* (1986) FEBS Lett., 209 13-17). The H55 protein was desorbed from the lysine - Sepharose column using a 0.5M L-arginine - containing buffer and was then concentrated by ultrafiltration using a 10,000 molecular weight cut-off membrane (Centriprep-10, Amicon Ltd). The ultrafiltered retentate had a volume of 0.95 ml and contained 4,800 IU by fibrin plate assay.

20

25

(2) The second purification example relates to 12 litres conditioned media from the CHO cell line 16MC.1 (Example 14).

30

All glassware and columns were autoclaved prior to use, all buffers were 0.2 $\mu$  sterile filtered. The chromatography system used (A Waters 650 advanced protein purification system) was sanitised with 2M NaOH. 500ml of lysine Sepharose Fast Flow was packed into an Amicon industrial glass 70mm column and

35



- 47 -

- packed at linear flow rate of  $300 \text{ cm.h}^{-1}$  with phosphate-buffered saline (Dulbecco A). Upon completion of packing (determined when the bed height remains constant) the column was equilibrated with a
- 5 further 4 bed volumes of phosphate-buffered saline (PBS). Conditioned media (12L) that had been filtered through an  $8\mu$  polypropylene filter was then applied at a linear velocity of  $100 \text{ cm.h}^{-1}$ .
- 10 The column was then washed with PBS containing 1M NaCl at a linear velocity of  $100 \text{ cm.h}^{-1}$  for 5 bed volumes. The column was then eluted using a linear gradient of 0-10mM EACA in PBS/1M NaCl (over 6 bed
- 15 volumes). Elution was monitored by following 280nm adsorption of the protein eluted by the EACA. 73mg, as determined by fibrin plate analysis, of H55 was eluted in 1L of solution.
- 20 The eluted pool from above was combined with a similar run to give a solution containing 132mg of H55 in 2.5L. This material was concentrated using an Amicon 8400 stirred ultrafiltration cell containing an Amicon YM-30 ultrafiltration membrane. The
- 25 ultrafiltration was performed at 50 psi using nitrogen to pressurise the system. The ultrafiltration was continued until the solution was reduced in volume to 50ml when 300ml of 0.5M
- 30 arginine, 0.2M NaCl, 20mM Tris/HCl, 0.01% Tween 80pH 7.4 buffer was added. Ultrafiltration was continued until the volume was again reduced to 50ml when a further 300ml of the above buffer was added. The
- 35 volume was reduced to 25ml containing 120mg of H55. Ultrafiltration/diafiltration gave a yield of 91%. Upon completion of diafiltration the material was stored frozen at  $-40^\circ\text{C}$ .

- 48 -

In the figures:

Fig. 1 Plasmid pDH55i

5 Fig. 2 Plasmid pDH55  
signal = t-PA signal sequence

Fig. 3 Plasmid pDH56i

10 Fig. 4 Plasmid pDH56  
signal = t-PA signal sequence.

Fig. 5A Construction of plasmid pDB546

15 Fig. 5B Construction of plasmid pDB545.


Fig. 5C Construction of plasmid pDB549.

Claims-A

1. A hybrid plasminogen activator (PA) which comprises kringle 5 or kringles 4 and 5 of plasminogen linked to the B-chain of t-PA or u-PA via an amino acid sequence comprising, respectively, the t-PA cleavage site between residues 275 and 276 and the cysteine residue 264 of t-PA or the u-PA cleavage site between residues 158 and 159 and the cysteine residue 148 of u-PA.

10

2. A hybrid plasminogen activator according to claim 1 of the formula:



15 where  $B^t$  comprises residues 276-527 of t-PA,  $m$  is 0 or 1,  $K_4^P$  and  $K_5^P$  represent kringle domains 4 and 5 derived from plasminogen and each of  $Z_3$ ,  $Z_4$  and  $Z_5$  represents, as appropriate, an optional N-terminal amino acid sequence or a bond or a linking sequence of amino acids which may be  
20 introduced synthetically during the preparation of the hybrid PA and/or derived from native plasminogen and/or t-PA sequences, the sequence  $Z_5$  comprising at least residues cys-264 and arg-275 of t-PA.

25 3. A hybrid plasminogen activator according to claim 2 wherein  $m$  is 1,  $Z_4$  represents the native plasminogen inter-domain sequence between plasminogen kringle domains 4 and 5 and  $Z_3$  has at its N-terminus the sequence [GARSYQ] or [SYQ] corresponding to the L- and S-chain forms of t-PA, and  
30 comprises some or all of the native plasminogen inter-domain sequence between plasminogen kringle domains 3 and 4.

4. A hybrid plasminogen activator according to claim 3 wherein  $Z_3$  comprises plasminogen residues 347-357.

35

5. A hybrid plasminogen activator according to claim 2 wherein m is 0 and Z<sub>4</sub> has at its N-terminus the sequence [GARSYQ] or [SYQ] corresponding to the L- and S-chain forms of t-PA, and comprises some or all of the native plasminogen inter-domain sequence between plasminogen kringle domains 4 and 5.

6. A hybrid plasminogen activator according to claim 5 wherein Z<sub>4</sub> comprises plasminogen residues 443-461.

10

7. A hybrid plasminogen activator according to any one of claims 2 to 6 wherein Z<sub>5</sub> is selected from:

1. [AAPSTCGLRQYSQPQFR]
- 15 2. [AAPSTCGLRQYSQPQFQ]
3. [STCGLRQYSQPQFR]

(single letter amino acid notation)

20 8. GARSYQ/plasminogen 347-541/t-PA 262-527 including one and two chain variants, gly<sub>3</sub> and ser<sub>1</sub> variants, and mixtures thereof.

9. GARSYQ/plasminogen 443-541/t-PA 262-527 including one  
25 and two chain variants, gly<sub>3</sub> and ser<sub>1</sub> variants, and mixtures thereof.

10. GARSYQ/plasminogen 347-546/u-PA 137-411 including one  
and two chain variants, gly<sub>3</sub> and ser<sub>1</sub> variants, and  
30 mixtures thereof.

11. GARSYQ/plasminogen 443-546/u-PA 137-411 including one  
and two chain variants, gly<sub>3</sub> and ser<sub>1</sub> variants, and  
mixtures thereof.

35


-51-

12. A hybrid plasminogen activator according to any one of claims 1 to 11 expressed using chinese hamster ovary, HeLa, E. coli or Spodoptera frugiperda cells.
- 5 13. A hybrid plasminogen activator according to any preceding claim where the catalytic site essential for fibrinolytic activity is blocked by a removable blocking group.
- 10 14. N,N-Dimethyl-4-aminobenzoyl two chain SYQ/plasminogen 347-541/t-PA 262-527.
15. 4-Anisoyl SYQ/plasminogen 347-541/t-PA 262-527.
- 15 16. 4-Anisoyl SYQ/plasminogen 443-541/t-PA 262-527.
17. A pharmaceutical composition comprising a hybrid plasminogen activator according to any preceding claim in combination with a pharmaceutically acceptable carrier.
- 20 18. A hybrid plasminogen activator according to any of claims 1 to 16 for use as an active therapeutic substance.
19. A hybrid plasminogen activator according to any of  
25 claims 1 to 16 for use in the treatment of thrombotic diseases.
20. Use of a hybrid plasminogen activator according to any of claims 1 to 16 for the manufacture of a medicament for  
30 the treatment of thrombotic diseases.
21. A method of treating thrombotic diseases which comprises administering to the sufferer an effective non-toxic amount of a hybrid plasminogen activator according to  
35 any of claims 1 to 16.

22. A process for preparing a hybrid plasminogen activator according to claim 1 or 13 which process comprises expressing DNA encoding said hybrid plasminogen activator in a recombinant host cell and recovering the hybrid  
5 plasminogen activator product, and thereafter optionally blocking the catalytic site essential for fibrinolytic activity with a removable blocking group.

1/7


Fig. 1



A - Vector

2/7

Fig. 2




- A - Vector
- B - Signal
- C - (K4K5)p
- D - Bt



3/7


Fig. 3



A - Vector


4/7

Fig. 4




- A - Vector
- B - Signal
- C - (K5)p
- D - Bt

Fig. 5A




6/7

Fig. 5B



7/7


Fig. 5C



# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 91/01455

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (If several classification symbols apply, indicate all) <sup>6</sup>		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.Cl.5	C 12 N 15/62	C 12 N 9/72 A 61 K 37/547
C 12 N 15/58		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
Int.Cl.5	C 12 N A 61 K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are included in the Fields Searched <sup>8</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b>		
Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
Y	EP,A,0297882 (BEECHAM GROUP LTD) 4 January 1989, see abstract; claims ---	1-22
Y	EP,A,0293934 (ZYMOGENETICS INC.) 7 December 1988, see abstract; claims ---	1-12,17 -22
Y	EP,A,0292326 (BEECHAM GROUP PLC) 23 November 1988, see abstract; claims ---	1-22
Y	Protein Engineering, volume 1, no. 6, December 1987, IRL Press LTD, (Oxford, GB) T.J.R. Harris: "Second-generation plasminogen activators", pages 449-458, see page 455, right-hand column, 4th paragraph - page 456, right-hand column, 1st paragraph ---	1-12,17 -22
Y	WO,A,8805081 (CETUS CORPORATION) 14 July 1988, see abstract; claims --- -/-	1-12,17 -22
<p><sup>10</sup> Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
26-11-1991	17. 12. 91	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	 Danielle van der Haas	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
Y	WO,A,8910401 (COLLABORATIVE RESEARCH INC.) 2 November 1989, see abstract; claims ---	1-12,17 -22
Y	EP,A,0379890 (FUJISAWA PHARMACEUTICAL CO.) 1 August 1990, see abstract; claims ---	1-12,17 -22
P,Y	EP,A,0397366 (BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA) 14 November 1990, see abstract; claims ---	1-12,17 -22
A	WO,A,9009437 (BOEHRINGER MANNHEIM GmbH) 23 August 1990, see claims ---	3
A	EP,A,0290118 (BEECHAM GROUP PLC) 09 November 1988, see abstract; claims -----	

## FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATION WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE <sup>1</sup>

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claim numbers because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claim 21 is directed to a method of treatment of the human body the search has been carried out and based on the alleged effects of the compound.
2. ☐ Claim numbers because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claim numbers because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING <sup>2</sup>

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the international searching authority did not invite payment of any additional fee.

## Remark on Protest.

- ☐ The additional search fees were accompanied by applicant's protest.  
☐ No protest accompanied the payment of additional search fees.



**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.**

GB 9101455

SA 50887

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 10/12/91  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0297882	04-01-89	AU-A- 1853388 JP-A- 1080287	19-01-89 27-03-89
EP-A- 0293934	07-12-88	AU-A- 1741088 JP-A- 1085078	08-12-88 30-03-89
EP-A- 0292326	23-11-88	JP-A- 1165379	29-06-89
WO-A- 8805081	14-07-88	AU-A- 8309387 EP-A- 0273774	11-08-88 06-07-88
WO-A- 8910401	02-11-89	AU-A- 3410289	24-11-89
EP-A- 0379890	01-08-90	AU-A- 4862790	23-08-90
EP-A- 0397366	14-11-90	AU-A- 5478590 CA-A- 2016236 JP-A- 3087188	15-11-90 09-11-90 11-04-91
WO-A- 9009437	23-08-90	DE-A- 3903581 AU-A- 5047090 CA-A- 2025900 EP-A- 0382174 JP-T- 3500724	16-08-90 05-09-90 08-08-90 16-08-90 21-02-91
EP-A- 0290118	09-11-88	JP-A- 63251084	18-10-88

EPO FORM P009

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

11

11

11

11